These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 14744499)

  • 41. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
    Harrison MR; Hahn NM; Pili R; Oh WK; Hammers H; Sweeney C; Kim K; Perlman S; Arnott J; Sidor C; Wilding G; Liu G
    Invest New Drugs; 2011 Dec; 29(6):1465-74. PubMed ID: 20499131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 2-Methoxyestradiol, an endogenous estrogen metabolite, sensitizes radioresistant MCF-7/FIR breast cancer cells through multiple mechanisms.
    Salama S; Diaz-Arrastia C; Patel D; Botting S; Hatch S
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):231-9. PubMed ID: 21392897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor.
    Brahn E; Banquerigo ML; Lee JK; Park EJ; Fogler WE; Plum SM
    J Rheumatol; 2008 Nov; 35(11):2119-28. PubMed ID: 18792999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines.
    Jiang H; Gao W; Sze DM; Xiong H; Hou J
    Int J Hematol; 2007 Dec; 86(5):429-37. PubMed ID: 18192112
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent Advances in chemistry and pharmacology of 2-methoxyestradiol: An anticancer investigational drug.
    Kumar BS; Raghuvanshi DS; Hasanain M; Alam S; Sarkar J; Mitra K; Khan F; Negi AS
    Steroids; 2016 Jun; 110():9-34. PubMed ID: 27020471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIF-1 alpha inhibition ameliorates neonatal brain damage after hypoxic-ischemic injury.
    Chen W; Jadhav V; Tang J; Zhang JH
    Acta Neurochir Suppl; 2008; 102():395-9. PubMed ID: 19388354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
    Chauhan D; Li G; Auclair D; Hideshima T; Richardson P; Podar K; Mitsiades N; Mitsiades C; Li C; Kim RS; Munshi N; Chen LB; Wong W; Anderson KC
    Blood; 2003 May; 101(9):3606-14. PubMed ID: 12480690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells.
    Lee YM; Ting CM; Cheng YK; Fan TP; Wong RN; Lung ML; Mak NK
    Cancer Lett; 2008 Sep; 268(2):295-307. PubMed ID: 18492602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors.
    Schumacher G; Neuhaus P
    J Cancer Res Clin Oncol; 2001 Jul; 127(7):405-10. PubMed ID: 11469676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypoxia inducible factor as a cancer drug target.
    Welsh SJ; Powis G
    Curr Cancer Drug Targets; 2003 Dec; 3(6):391-405. PubMed ID: 14683498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.
    Matei D; Schilder J; Sutton G; Perkins S; Breen T; Quon C; Sidor C
    Gynecol Oncol; 2009 Oct; 115(1):90-96. PubMed ID: 19577796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
    Lakhani N; Sparreboom A; Venitz J; Dahut WL; Figg WD
    Anticancer Drugs; 2006 Sep; 17(8):977-83. PubMed ID: 16940808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamido-triazole (CAI) and 2-methoxyestradiol (2ME2).
    Cruysberg LP; Franklin AJ; Sanders J; Self C; Yuan P; Csaky KG; Robinson MR; Kohn EC; Edelhauser HF
    Retina; 2005 Dec; 25(8):1022-31. PubMed ID: 16340533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro assessment of a computer-designed potential anticancer agent in cervical cancer cells.
    Visagie MH; Jaiswal SR; Joubert AM
    Biol Res; 2016 Nov; 49(1):43. PubMed ID: 27806731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.
    Tan C; de Noronha RG; Roecker AJ; Pyrzynska B; Khwaja F; Zhang Z; Zhang H; Teng Q; Nicholson AC; Giannakakou P; Zhou W; Olson JJ; Pereira MM; Nicolaou KC; Van Meir EG
    Cancer Res; 2005 Jan; 65(2):605-12. PubMed ID: 15695405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2.
    Bu SZ; Huang Q; Jiang YM; Min HB; Hou Y; Guo ZY; Wei JF; Wang JW; Ni X; Zheng SS
    Apoptosis; 2006 Mar; 11(3):413-25. PubMed ID: 16538384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of STAT3/5 and Bcl-2/xL in 2-methoxyestradiol-induced endoreduplication of nasopharyngeal carcinoma cells.
    Ting CM; Wong CK; Wong RN; Lo KW; Lee AW; Tsao GS; Lung ML; Mak NK
    Mol Carcinog; 2012 Dec; 51(12):963-72. PubMed ID: 22006341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
    Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
    Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Bone Sparing Effects of 2-Methoxyestradiol Are Mediated via Estrogen Receptor-α in Male Mice.
    Eriksson AL; Wilhelmson AS; Fagman JB; Ryberg H; Koskela A; Tuukkanen J; Tivesten Å; Ohlsson C
    Endocrinology; 2016 Nov; 157(11):4200-4205. PubMed ID: 27631553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
    Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
    Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.